top of page
Waterside Pharma-16.jpg

Welcome to Waterside Pharmaceuticals

Waterside Pharmaceuticals is a UK-based life sciences and agriculture company based in Aberdeenshire, Scotland, focused on the cultivation, importation and distribution of high-quality medicinal cannabis.


We combine pharmaceutical standards with innovative and sustainable practices to ensure consistent, traceable and patient-safe products, from cultivation through to final supply. Our fully indoor facility is built for total environmental control and automation, with operations designed to meet the highest standards of quality, compliance and care.

Redefining Medicinal Cannabis

Waterside Pharmaceuticals brings together pharmaceutical-grade precision and next-generation vertical farming to cultivate consistent cannabis plants to be used as a starter material for final product medicines in a fully indoor facility based in Aberdeenshire, Scotland.

Our Total Controlled Environment Agriculture (TCEA) system allows us to finely regulate lighting, climate, irrigation, and nutrition, delivering stable cannabinoid and terpene profiles, batch after batch.

We operate to GACP and GDP standards but apply GMP principles throughout our cultivation activities with the aim of becoming GMP certified in the next year or two. 

 

By growing locally, we aim to reduce the UK's dependence on imports, supporting a more secure, high-quality supply of medical cannabis for patients across the country.

Waterside Pharma-53.jpg

Cultivating with Purpose: Precision, Sustainability, and Patient Focus

We’re taking a thoughtful, science-led approach to medicinal cannabis cultivation, combining pharmaceutical precision, sustainable practices, and a deep commitment to patient wellbeing.

UK Based

Production

UK map

We cultivate in the UK, ensuring a local, consistent, and reliable supply, reducing dependence on imports and improving patient access.

Pharmaceutical-Grade

Quality

Medicinal Drugs

We operate to the highest GACP and GDP standards, ensuring strict quality control, traceability, and consistency in every batch.

Total Controlled Environment Agriculture (TCEA)

Vertical Farming

Our fully indoor, pesticide-free cultivation facility creates precise, replicable growing conditions, guaranteeing premium-quality medicinal cannabis.

Sustainability

Planet Earth Icon

Our approach ensures a responsible, eco-friendly cultivation process while maintaining the highest standards of quality and efficiency.

Innovation

Plant Innovation

By integrating cutting-edge technology and advanced cultivation methods, we are continuously improving consistency, efficiency, and product quality.

Patient-Centered Care

Doctor Patient

Our priority is delivering safe, high-quality, and consistent medicinal cannabis.

Key Milestones in Our Journey

Waterside Pharma-33.jpg

UK Re-Classifies Cannabis for Medical Use

In Nov 2018, the UK reclassified cannabis‑based medicinal products (CBPMs) to Schedule 2, allowing specialist doctors to prescribe unlicensed “specials” on a named‑patient basis, enabling tightly regulated access for patients in need

2018

Innovation Through Research

We began investing in research and detailed business planning, building an understanding of patient needs, market dynamics, and regulatory pathways to guide our long-term vision, sustainable growth, and commitment to safe, effective, and accessible cannabis-based medicines.

2020

Foundation of Waterside Pharmaceuticals

Waterside Pharmaceuticals was founded with a clear purpose: to develop a responsible, UK-based supply of high-quality cannabis-based medicines. Rooted in science, sustainability, and patient care, and built to meet evolving clinical and regulatory expectations.

2022

Home Office Cultivation Licence Secured

We secured a Home Office Schedule 1 Controlled Drugs licence to cultivate and supply cannabis as starter material. This milestone allowed us to commence operations and reflected our commitment to regulatory excellence and patient-focused innovation.

2024

Elevating Standards: Awarded WDA(H) from the MHRA

Early 2025, we were awarded Wholesale Distribution Authorisation (Human) [WDA(H)] from the MHRA, reinforcing our commitment to GDP compliance, regulatory excellence, and the safe, reliable distribution of medical cannabis across the UK.

2025

Achieving GMP Certification by 2026

We aim to achieve GMP certification, ensuring our processes meet the highest pharmaceutical quality standards. This milestone will demonstrate our commitment to excellence, patient safety, and delivering consistently high-quality cannabis-based medicines.

2026

Waterside Pharma-23.jpg

CONNECT WITH US

Multi choice
bottom of page